Category - Developments

Developments

Hepion’s rencofilstat IP estate strengthened with new European patent

The European Patent Office granted a patent to Hepion Pharmaceuticals (NASDAQ:HEPA) covering the innovative formulation of Hepion’s lead cyclophilin inhibitor, rencofilstat. The newly granted European patent also...

March 2, 2023

Developments

FDA grants orphan drug to Aravive’s batiraxcept for pancreatic cancer

The FDA granted orphan drug designation for Aravive’s (NASDAQ:ARAV) batiraxcept for the treatment of pancreatic ductal adenocarcinoma cancer (PDAC). In a statement, Gail McIntyre, Ph.D., DABT, CEO of Aravive, said three...

March 1, 2023

Developments

Atossa doses first patient in Phase 2 breast cancer study

Atossa Therapeutics (NASDAQ:ATOS) dosed the first patient in the Phase 2 EVANGELINE non-inferiority clinical trial of Atossa’s patented selective estrogen receptor modulator, (Z)-endoxifen, and exemestane plus goserelin...

February 23, 2023

Developments

Theralase presents Phase 2 NMIBC interim data at ASCO GU

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) presented interim data from its Phase 2 (Study II) clinical study at the American Society of Clinical Oncology (ASCO) Genito Urinary Cancer Symposium via a moderated poster...

February 23, 2023

Developments

SenterCare in pact to bring aging-at-home-safely technology to Japan

Closely-held SenterCare, a member of the Trendlines Group of Israel, and Nozomi MedAlliance established an alliance to bring SenterCare’s advanced aging-at-home-safely technology to the Japanese market. SenterCare has...

February 21, 2023

Developments

IntelGenx receives USPTO notice of allowance for loxapine Orange Book eligible patent

The United States Patent and Trademark Office has granted a notice of allowance for IntelGenx’s (TSX:IGX; OTCQB:IGXT) U.S. patent application entitled, “Loxapine Film Oral Dosage Form.” The film formulation patent...

February 21, 2023

Developments

Theralase named to TSXV 2023 Venture 50

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) was named to the TSX Venture Exchange’s 2023 Venture 50, an annual ranking of top-performing companies from five industry sectors. Theralase was recognized in the clean...

February 21, 2023

Developments

Freedom Holding to acquire Maxim Group for $400-million

Freedom Holding (NASDAQ:FRHC), a multi-national financial services firm, agreed to acquire Maxim Group and its registered investment advisory affiliate, Maxim Financial Advisors, for a combination of cash and common...

February 17, 2023

Developments

Aravive to present positive updated data at ASCO GU cancer symposium

Aravive (NASDAQ:ARAV) will present updated results from its ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU)...

February 14, 2023

Developments

Cognition completes enrollment in Phase 2 SEQUEL study in AD

Cognition Therapeutics (NASDAQ:CGTX) completed enrollment in the randomized, double-blind Phase 2 SEQUEL study of its CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease. The study was designed to assess...

February 9, 2023

Category - Developments

Subscribe